CONTEXT

- UNICEF procures Yellow Fever (YF) vaccine on behalf of approximately 40 countries, mainly in the African region, in support of Yellow Fever control programmes.

- There are four manufacturers of WHO pre-qualified YF vaccines. Availability through UNICEF has increased over the last 5 years, while suppliers’ combined production capacity has increased.

- Routine and outbreak response supply through UNICEF has been secured through 2024. Supply for preventive campaign demand is partly secured.

- With the Eliminating Yellow fever Epidemics (EYE) strategy inception in 2017, the programmatic focus has emphasized on the need to achieve high and sustained immunization coverage. The strategy projects high demand for YF vaccines until preventive mass vaccination campaigns (PMVC) have been conducted in all at-risk countries.

SUPPLY & DEMAND

- There are three streams of demand for YF vaccine procured through UNICEF: routine immunization programmes representing approximately 30% of the procured volumes, preventative mass vaccination campaigns representing approximately 70% of the procured volumes and the demand for the Emergency Stockpile to respond to outbreaks (6 million doses).

- Since the launch of EYE Strategy at the beginning of 2017, with increasing demand for YF vaccines, the volumes procured through UNICEF have been also progressively increasing reaching nearly 94 million doses annual procurement in 2022.

- By 2024, the demand for YF vaccines to be channelled through UNICEF is estimated to increase to 100 million doses. This increase is predominantly expected to be linked to the increased use of YF vaccine in preventive campaigns.

- UNICEF project that the annual supply for YF vaccines for PMVCs will reach approximately 60 million doses by 2025.

- Demand from routine programmes has been (and is expected to remain) relatively stable and is projected to increase by an estimated 7% annually as countries continue strengthening their health systems and more countries introduce the vaccine.

ISSUES & CHALLENGES

Demand for PMVCs through UNICEF will continue to exceed the projected availability through 2024.

Opportunities for excess availability may be realized during 2025-2026.

Delay in country introductions may have impact on the projected demand beyond 2024.

Continued ICG Emergency Stockpile requirement of 6 million doses being available at all times.

Improved long-term forecasting for preventative campaigns demand both in terms of timing and volume remains a focus.

LOOKING AHEAD

UNICEF supports the goals of EYE strategy and will continue advocating for reinforcement of routine/ routine introductions into all at-risk countries.

UNICEF, together with partners, will continue to review YFV supply availability against demand requirements to assess and coordinate YFV allocations and prioritization for routine, emergency response and preventative campaigns.

UNICEF will continue to share country forecasts with manufacturers to improve visibility and information on supply and demand.

FURTHER QUESTIONS OR ADDITIONAL INFORMATION? PLEASE CONTACT:

Antonia Naydenov
Contracts Specialist
anaydenov@unicef.org